Research programme: serotonin psychedelics - Mydecine Innovations Group
Alternative Names: Mycological medications - Mydecine Innovations Group; Nature-sourced psychedelic-assisted therapeutics - Mydecine Innovations Group; Psychedelic therapy enhancers - Mydecine Innovations Group; Psychedelic-assisted psychotherapy - Mydecine Innovations Group; Tryptamines - Mydecine Innovations GroupLatest Information Update: 28 Jul 2024
At a glance
- Originator Mydecine Innovations Group
- Developer Applied Pharmaceutical Innovation; Mydecine Innovations Group
- Class Neuropsychotherapeutics; Tryptamines
- Mechanism of Action Serotonin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mental disorders
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Mental-disorders in Canada
- 28 Jul 2024 No recent reports of development identified for research development in Mental-disorders in USA
- 16 Mar 2021 Mydecine Innovations Group signs R&D agreement with Imperial College of Science, Technology and Medicine for psychedelics